Advertisement

The Editor's Roundtable: JUPITER Follow-Up

  • Vincent E. Friedewald
    Correspondence
    Corresponding author: Tel: 512-264-1611; fax: 512-264-8939
    Affiliations
    Associate Editor, The American Journal of Cardiology, Clinical Professor, Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas USA, and Research Professor, College of Science, University of Notre Dame, Notre Dame, Indiana
    Search for articles by this author
  • Christie M. Ballantyne
    Affiliations
    Professor and Chief, Section of Cardiovascular Research, Interim Chief, Section of Cardiology, Director, Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas USA, and Director, Center for Cardiovascular Disease Prevention, The Methodist Hospital and Baylor College of Medicine, Houston, Texas
    Search for articles by this author
  • Michael H. Davidson
    Affiliations
    Professor, Director of Preventive Cardiology, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
    Search for articles by this author
  • Antonio M. Gotto Jr.
    Affiliations
    Stephen and Suzanne Weiss Dean and Professor of Medicine, Weill Cornell Medical College, New York, New York
    Search for articles by this author
  • Paul M. Ridker
    Affiliations
    Eugene Braunwald Professor of Medicine, Harvard Medical School, and Director, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, Massachusetts
    Search for articles by this author
  • William C. Roberts
    Affiliations
    Editor-in-Chief, The American Journal of Cardiology and Baylor University Medical Center Proceedings, Executive Director, Baylor Heart and Vascular Institute, Baylor University Medical Center, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas, Texas
    Search for articles by this author
      This activity is supported by a grant from AstraZeneca , Wilmington, Delaware.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.H.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.P.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Kritek P.
        • Campion E.W.
        JUPITER clinical directions—polling results.
        N Engl J Med. 2009; 360: e14
        • Hlatky M.A.
        Expanding the orbit of primary prevention—moving beyond JUPITER.
        N Engl J Med. 2008; 359: 2280
        • Boekholdt S.M.
        • Kastelein J.J.P.
        C-reactive protein and cardiovascular risk: more fuel to the fire.
        Lancet. 2010; 375: 95-96
        • Goldstein L.B.
        JUPITER and the world of stroke medicine.
        Lancet Neurol. 2009; 8: 129-131
        • Glynn R.J.
        • Danielson E.
        • Fonseca F.A.H.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.P.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Ridker P.M.
        A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
        N Engl J Med. 2009; 360: 1851-1861
        • The Emerging Risk Factors Collaboration
        C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
        Lancet. 2010; 375: 132-140
        • Girman C.J.
        • Rhodes T.
        • Mercuri M.
        • Pyörälä K.
        • Kjekshus J.
        • Pedersen T.R.
        • Beere P.A.
        • Gotto A.M.
        • Clearfield M.
        • 4S Group and the AFCAPS/TexCAPS Research Group
        The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
        Am J Cardiol. 2004; 93: 136-141
        • Nissen S.E.
        • Tuzcu E.M.
        • Schoenhagen P.
        • Crowe T.
        • Sasiela W.J.
        • Tsai J.
        • Orazem J.
        • Magorien R.D.
        • O'Shaughnessy C.
        • Ganz P.
        • Reversal of Atherosclerosis With Aggressive Lipid lowering (REVERSAL) Investigators
        Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
        N Engl J Med. 2005; 352: 29-38
        • Pfeffer M.A.
        • Sacks F.M.
        • Moyé L.A.
        • Brown L.
        • Rouleau J.L.
        • Hartley L.H.
        • Rouleau J.
        • Grimm R.
        • Sestier S.
        • Wickemeyer W.
        • Cole T.G.
        • Braunwald E.
        • the CARE Investigators
        Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients.
        Am J Cardiol. 1995; 76: 98C-106C
        • Murphy S.A.
        • Cannon C.P.
        • Wiviott S.D.
        • McCabe C.H.
        • Braunwald E.
        Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) trial.
        J Am Coll Cardiol. 2009; 54: 2358-2362
        • Yang E.Y.
        • Nambi V.
        • Tang Z.
        • Virani S.S.
        • Boerwinkle E.
        • Hoogeveen R.C.
        • Astor B.C.
        • Mosley T.H.
        • Coresh J.
        • Chambless L.
        • Ballantyne C.M.
        Clinical implications of JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a U.S. population: insights from the ARIC (Atherosclerosis Risk in Communities) study.
        J Am Coll Cardiol. 2009; 54: 2388-2395
      1. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        (Accessed on March 18, 2010)
        • Ford I.
        • Murray H.
        • Packard C.J.
        • Shepherd J.
        • Macfarlane P.W.
        • Cobbe S.M.
        • West of Scotland Coronary Prevention Study Group
        Long-term follow-up of the West of Scotland Coronary Prevention Study.
        N Engl J Med. 2007; 357: 1477-1486
        • Enriquez J.R.
        • Pratap P.
        • Zbilut J.P.
        • Calvin J.E.
        • Annabelle S.
        • Volgman A.S.
        Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, β-blockers, or statins.
        Gender Med. 2008; 5: 53-61
        • Sever P.S.
        • Poulter N.R.
        • Dahlof B.
        • Wedel H.
        • Beevers G.
        • Caulfield M.
        • Collins R.
        • Kjeldsen S.
        • Kristinsson A.
        • McInnes G.
        • Mehlsen J.
        • Nieminen M.S.
        • O'Brien E.T.
        • Östergren J.
        The Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm: extended observations 2 years after trial closure.
        Eur Heart J. 2008; 29: 499-508
        • Kjekshus J.
        • Apetrei E.
        • Barrios V.
        • Böhm M.
        • Cleland J.G.
        • Cornel J.H.
        • Dunselman P.
        • Fonseca C.
        • Goudev A.
        • Grande P.
        • Gullestad L.
        • Hjalmarson A.
        • Hradec J.
        • Jánosi A.
        • Kamenský G.
        • Komajda M.
        • Korewicki J.
        • Kuusi T.
        • Mach F.
        • Mareev V.
        • McMurray J.J.
        • Ranjith N.
        • Schaufelberger M.
        • Vanhaecke J.
        • van Veldhuisen D.J.
        • Waagstein F.
        • Wedel H.
        • Wikstrand J.
        • CORONA Group
        Rosuvastatin in older patients with systolic heart failure.
        N Engl J Med. 2007; 357: 2248-2261
        • McMurray J.J.V.
        • Kjekshus J.
        • Gullestad L.
        • Dunselman P.
        • Hjalmarson A.
        • Wedel H.
        • Lindberg M.
        • Waagstein F.
        • Grande P.
        • Hradec J.
        • Kamensky G.
        • Korewicki J.
        • Kuusi T.
        • Mach F.
        • Ranjith N.
        • Wikstrand J.
        • CORONA Study Group
        Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
        Circulation. 2009; 120: 2188-2196
        • Everett B.M.
        • Glynn R.J.
        • MacFadyen J.G.
        • Paul M Ridker P.M.
        Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).
        Circulation. 2010; 121: 143-150
        • The Look AHEAD Research Group
        The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it.
        Obesity. 2006; 14: 737-752
        • Belalcazar M.
        • Reboussin D.
        • Haffner S.
        • Hoogeveen R.
        • Tracy R.
        • Kriska A.
        • Schwenke D.
        • Pi-Sunyer X.
        • Ballantyne C.
        Improvement in glucose control with lifestyle intervention reduces C-reactive protein in obese subjects with type 2 diabetes: the Look AHEAD study.
        Circulation. 2009; 120: S473-S474
      2. Virani SS, Woodard L, Robinson C, Pietz KC, Urech TH, Ballantyne CM, Petersen LA. Has LDL cholesterol (LDL-C) and non-HDL-cholesterol (non-HDL-C) goal attainment improved 7 years after Adult Treatment Panel III (ATP III) guidelines were published? Circ Cardiovasc Qual Outcomes. In press.

      Linked Article

      • Inflammation and Atherothrombotic Disease
        American Journal of CardiologyVol. 108Issue 8
        • Preview
          The remarks of Paul Ridker, MD, in the recent “Editor's Roundtable”1 require comment. Ridker declares high-sensitivity C-reactive protein (hsCRP) to be a major risk factor for atherothrombotic disease (ATD). Dr. Ridker is in error in this statement. If hsCRP were a major ATD risk factor, then subjects with the highest levels of hsCRP should have the highest risk for ATD, and as Ridker himself has pointed out, natives of sub-Saharan Africa frequently have malaria, and those who do have malaria have extremely high levels of hsCRP but do not have ATD events to any significant degree.
        • Full-Text
        • PDF